Literature DB >> 12876669

Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes.

Renato Zambello1, Gianpietro Semenzato.   

Abstract

The most relevant criterion for recognizing chronic granular lymphocyte (GL) proliferations, defined as lymphoproliferative disease of GL (LDGL), has been historically based on the number of the proliferating cells displaying typical GL morphology. With the extensive development of immunological and molecular techniques, two major groups of LDGL have been recognized, one belonging to the T-cell and the other to the NK cell lineage. The recent definition of a series of receptors of NK cells (NKR) and the identification of the specific targets recognized has expanded our knowledge of the properties of these cells and the discrimination between functional reactive and pathological proliferations. Some of these receptors are expressed by GL of T-cell lineage, suggesting a possible involvement in the genesis of GL proliferation. Following an extensive description of NKR in humans, this review will summarize the recent data on phenotypic and functional characteristics of NKR expressed by proliferating GL in patients with LDGL, discussing their role in this disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12876669     DOI: 10.1016/s0037-1963(03)00134-3

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  10 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

Review 2.  Natural killer cells in inflammatory heart disease.

Authors:  SuFey Ong; Noel R Rose; Daniela Čiháková
Journal:  Clin Immunol       Date:  2016-11-25       Impact factor: 3.969

Review 3.  T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias.

Authors:  Rebecca J Watters; Xin Liu; Thomas P Loughran
Journal:  Leuk Lymphoma       Date:  2011-07-13

Review 4.  Large granular lymphocyte leukemia.

Authors:  Lubomir Sokol; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

5.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

Review 6.  Natural killer cell neoplasm: biology and pathology.

Authors:  Maria Francisca Ham; Young-Hyeh Ko
Journal:  Int J Hematol       Date:  2010-12-07       Impact factor: 2.490

7.  A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia.

Authors:  Xianghong Chen; Fanqi Bai; Lubomir Sokol; Junmin Zhou; Amy Ren; Jeffrey S Painter; Jinhong Liu; David A Sallman; Y Ann Chen; Jeffrey A Yoder; Julie Y Djeu; Thomas P Loughran; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

Review 8.  Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?

Authors:  Renato Zambello; Antonella Teramo; Gregorio Barilà; Cristina Gattazzo; Gianpietro Semenzato
Journal:  Front Immunol       Date:  2014-02-26       Impact factor: 7.561

9.  Emergence of a STAT3 mutated NK clone in LGL leukemia.

Authors:  Yiyi Yan; Thomas L Olson; Susan B Nyland; David J Feith; Thomas P Loughran
Journal:  Leuk Res Rep       Date:  2014-12-16

Review 10.  Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options.

Authors:  Giulia Calabretto; Antonella Teramo; Gregorio Barilà; Cristina Vicenzetto; Vanessa Rebecca Gasparini; Gianpietro Semenzato; Renato Zambello
Journal:  Cells       Date:  2021-10-19       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.